Drug Shortage Report for SANDOZ CANDESARTAN PLUS
Report ID | 210835 |
Drug Identification Number | 02420740 |
Brand name | SANDOZ CANDESARTAN PLUS |
Common or Proper name | CANDESARTAN |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE CANDESARTAN CILEXETIL |
Strength(s) | 25MG 32MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100TAB |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-11-20 |
Estimated end date | 2024-02-23 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2023-11-21 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2023-11-21 | English | Compare |
v2 | 2023-11-20 | French | Compare |
v1 | 2023-11-20 | English | Compare |
Showing 1 to 3 of 3